Open AccessClinical review considerations of class I PI3K inhibitors in hematolymphatic malignancies by Center for Drug Evaluation
Author(s) -
Limin Zou,
Yueli Qi,
Lin Tang,
Yong Du,
Meiyi Xiang,
Xiaoming Chen,
Jun Ma,
Ziqiang Yang
Publication year - 2022
Publication title -
chinese journal of cancer research/chinese journal of cancer research
Language(s) - English
Resource type - Journals
eISSN - 1993-0631
pISSN - 1000-9604
DOI - 10.21147/j.issn.1000-9604.2022.04.09
Subject(s) - medicine , authorization , adverse effect , food and drug administration , temsirolimus , drug , specialty , pi3k/akt/mtor pathway , pharmacology , intensive care medicine , family medicine , discovery and development of mtor inhibitors , apoptosis , biochemistry , chemistry , computer security , computer science